Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Outlook Therapeutics (OTLK) Accumulated Depreciation & Amortization (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $178510.0 as the latest value for Q2 2020.

  • Quarterly Accumulated Depreciation & Amortization fell 92.78% to $178510.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $178510.0 through Jun 2020, down 92.78% year-over-year, with the annual reading at $3.4 million for FY2019, 10.07% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2020 was $178510.0 at Outlook Therapeutics, up from $127551.0 in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $3.4 million in Q3 2019, with the low at $63776.0 in Q4 2019.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.4 million, with a median of $1.0 million recorded in 2016.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 444.34% in 2016, then plummeted 92.78% in 2020.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $669780.0 in 2016, then increased by 1.02% to $676624.0 in 2017, then grew by 21.64% to $823077.0 in 2018, then tumbled by 92.25% to $63776.0 in 2019, then soared by 179.9% to $178510.0 in 2020.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $178510.0, $127551.0, and $63776.0 for Q2 2020, Q1 2020, and Q4 2019 respectively.